Pinnacle IVD (Pinnacle) is pleased to announce the addition of the CovID Rapid Antigen Detection (RAD) test to its existing diagnostic test product line which includes the Pinnacle CovID NEO IgG / IgM Antibody Test.

The RAD is one of the first point of care antigen tests that requires no additional laboratory equipment, and is able to provide highly accurate results in just 15 minutes. It has been submitted to the FDA for Emergency Use Authorization (EUA), and promises to play a pivotal role in America’s fight against COVID-19 by providing quick, easy detection of active virus.

As pioneers in colon cancer screening and other in vitro diagnostics, Pinnacle has once more jumped to the forefront of the medical device industry, by pairing the RAD with cutting edge smartphone technology.

Due to this pairing much needed non-personal data and streaming analytics are able to be provided to the CDC, and other health agencies to aid them in implementing a targeted and effective strategy for combatting the COVID-19 pandemic.

“Our team is working collaboratively with strategic partners and the FDA to provide the highest quality testing protocols, educational materials, and risk mitigation strategies to ensure safe and effective use of our COVID-19 testing solutions,” said Charlie Balentine, President of Pinnacle IVD Corporation. “We believe pairing a point of care antibody test with a point of care antigen test can give providers the information they need to take action without dealing with the issues caused by increasingly long wait times for laboratory results. We’re also taking steps to scale our US and global manufacturing capacity to meet the overwhelming demand. We look forward to doing our part to get America and the world back to work, and our children back to school safely by providing practical, scalable COVID-19 testing solutions.”

In order to fast-track Emergency Use Authorization, Pinnacle is working closely with the FDA, it’s legal counsel Foley and Lardner LLP, Syntactx, a Clinical Research Organization, George Mason University and other partners to perform clinical studies. The results of those studies will be posted on Pinnacle’s website at https://www.pblabs.com/products/pinnacle-rapid-antigen-test . For sales and distribution information please contact 1-877-465-0826 or email covidinfo@pblabs.com in order to be connected with our authorized distributors.